Delta Diagnostics raises € 5.25 million Series A to revolutionize Biosensing Technology
Dutch start-up, Delta Diagnostics, a leader in label-free, multiplexed biosensing, announced that it has successfully secured Series A funding of €5.25 million. InnovationQuarter as a lifecycle investor provided funding through IQCapital after an initial investment by its proof-of-concept fund UNIIQ.
The funding round was made possible by a consortium of four investors: i&i Biotech Fund, Oost NL, InnovationQuarter and PhotonDelta. The investment will fuel the company’s ambitious vision of making rapid, sensitive, and low-cost biosensors accessible to all, transforming the Life Sciences industry and paving the way for novel and faster solutions in Life Sciences research.
Delta Diagnostics is a TNO spin-off that simplifies biosensing, the detection of biomolecules, using photonic integrated circuits. This cost-effective method accelerates Life Sciences research and enables multiplexing to analyze multiple biomolecules at once.
“Securing Series A funding marks a significant milestone for Delta Diagnostics, validating our technology and our vision to create multiplexed biosensing,” says Guy Dewil, CEO of Delta Diagnostics. “We are grateful to our investors for their support and strongly believe in our mission. This investment will accelerate the launch of our first product. It will unlock the full potential of our biosensing technology to drive discoveries in Life Sciences.”
“We are thrilled to accompany Delta Diagnostics in developing such a promising cutting-edge biosensing technology for both industry and academic research. We firmly believe that Delta´s technology can effectively bring a significant improvement in the biosensing arena. We are convinced, the interest of industrial partners for this technology maintains the committed team of Delta on the right trajectory to future success,” says Karel Kubias, Partner at i&i Biotech Fund.
“The Delta Diagnostics team is poised to disrupt the Life Sciences industry with our cutting-edge photonic biosensing technology,” says Bart de Boer, CTO of Delta Diagnostics. “Today’s scientists need more answers, faster. We create highly-sensitive label-free biosensing instruments enabling our customers to accelerate their research tremendously.”
With initial funding from TNO and UNIIQ, the company has grown into a highly experienced and well-balanced team, tirelessly perfecting its biosensing technology. The Series A funding will propel the company forward as its first product launch approaches. This will enable the company and its key partners from the Overijssel region to further develop next-generation biosensor systems for real-time biomolecule detection in samples.